Article
NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses.
Lancet (London, England) - 1 Jan 2000
García-Closas Montserrat, Malats Núria, Silverman Debra, Dosemeci Mustafa, Kogevinas Manolis, Hein David W, Tardón Adonina, Serra Consol, Carrato Alfredo, García-Closas Reina, Lloreta Josep, Castaño-Vinyals Gemma, Yeager Meredith, Welch Robert, Chanock Stephen, Chatterjee Nilanjan, Wacholder Sholom, Samanic Claudine, Torà Montserrat, Fernández Francisco, Real Francisco X, Rothman Nathaniel
Abstract excerpt
BACKGROUND: Many reported associations between common genetic polymorphisms and complex diseases have not been confirmed in subsequent studies. An exception could be the association between NAT2 slow acetylation, GSTM1 null genotype, and bladder-cancer risk. However, current evidence is based on meta-analyses of relatively small studies (range 23-374 cases) with some evidence of publication bias and study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.